Aurobindo Pharma aims to become debt free in 3 years sans Sandoz deal

 

HYDERABAD, Nov 24: Aurobindo Pharma expects to

become a debt free company in the three next years barring the

amount it is spending on acquisition of Sandoz products, a

senior official of the city-based company has said.

In September last year, the USD three billion drug

maker said its US subsidiary entered into an agreement to

acquire commercial operations and three manufacturing

facilities in America from Sandoz Inc, USA, a Novartis

Division, for USD 900 million.

“During the year, we will reduce between USD 150

million to USD 200 million debt, and we have already achieved

that..On the long-term front, based on the experience, which

we had in the last two or three quarters, and we are targeting

to achieve a zero debt in the next three years. That’s what we

are all seeing on the existing business… without considering

Sandoz,” Santhanam Subramanian, Aurobindo Chief Financial

officer said in a recent earnings call.

The company’s net debt decreased by USD 71 million

quarter-on-quarter to USD 522 million at the end of September

2019 against USD 593 million at the end of June 2019.

The majority of the company’s debt is denominated in

foreign currency.

The cash and bank balance was at USD 305 million.

Replying to query, Narayanan Govindarajan, Aurobindo

Pharma’s managing director, said they expect Federal Trade

Commission’s nod for the acquisition of the Sandoz products

and three facilities by next month or January.

The acquisition will add approximately 300 products

including projects in development as well as commercial and

manufacturing capabilities in the US, complementing and

expanding the group’s portfolio and pipeline and the

portfolio is expected to generate over USD 900 million in

sales for the first 12 months after completion of the

transaction for Aurobindo, the drug firm had earlier said.

Govindarajan said the company is expecting re-

inspection of its three manufacturing facilities, of which one

received warning letter and two others received “official

action indicated (OAI)” from the US Food and Drug

Administration.

“The inspection should happen before March or by

March-April time line is what our best estimate is. And we are

preparing ourselves to ensure that the inspection goes well,”

the official said. (PTI)